# Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

> **NCT04423731** · — · ACTIVE_NOT_RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 251 (actual)

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma
- Chemotherapy Effect
- Borderline Resectable Pancreatic Adenocarcinoma
- Pancreatectomy

## Interventions

- **DRUG:** Folfirinox

## Key facts

- **NCT ID:** NCT04423731
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423731, "Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04423731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*